Woodline Partners LP Buys 179,759 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Woodline Partners LP increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) by 1,919.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 189,126 shares of the company’s stock after purchasing an additional 179,759 shares during the quarter. Woodline Partners LP owned 0.24% of CRISPR Therapeutics worth $11,871,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. National Bank of Canada FI increased its position in shares of CRISPR Therapeutics by 41.1% during the 1st quarter. National Bank of Canada FI now owns 1,634 shares of the company’s stock valued at $101,000 after purchasing an additional 476 shares during the last quarter. Virginia Retirement Systems ET AL increased its position in shares of CRISPR Therapeutics by 6.4% during the 1st quarter. Virginia Retirement Systems ET AL now owns 18,200 shares of the company’s stock valued at $1,142,000 after purchasing an additional 1,100 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $289,982,000. Qube Research & Technologies Ltd increased its position in shares of CRISPR Therapeutics by 189.6% during the 1st quarter. Qube Research & Technologies Ltd now owns 81,592 shares of the company’s stock valued at $5,122,000 after purchasing an additional 53,414 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in shares of CRISPR Therapeutics by 49.4% during the 1st quarter. HighTower Advisors LLC now owns 49,883 shares of the company’s stock valued at $3,129,000 after purchasing an additional 16,496 shares during the last quarter. Institutional investors own 70.56% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $66.96 on Monday. The stock has a market capitalization of $5.22 billion, a P/E ratio of -8.14 and a beta of 1.97. CRISPR Therapeutics AG has a 1-year low of $42.51 and a 1-year high of $124.79. The business has a fifty day moving average price of $73.83 and a 200 day moving average price of $64.81.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported ($2.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.23) by ($0.17). The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $2.20 million. CRISPR Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,274.02%. The company’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter last year, the company earned $9.44 earnings per share. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -9.23 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 25,000 shares of the company’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $75.91, for a total transaction of $1,897,750.00. Following the completion of the sale, the chief executive officer now directly owns 290,279 shares in the company, valued at approximately $22,035,078.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 75,000 shares of company stock worth $5,108,500 in the last three months. 5.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Stifel Nicolaus upped their price objective on CRISPR Therapeutics from $55.00 to $69.00 in a research report on Tuesday, August 9th. Barclays downgraded CRISPR Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $99.00 to $88.00 in a research report on Tuesday, August 9th. Oppenheimer cut their price objective on CRISPR Therapeutics from $150.00 to $122.00 and set an “outperform” rating on the stock in a research report on Thursday, June 23rd. The Goldman Sachs Group cut their price objective on CRISPR Therapeutics from $52.00 to $46.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 24th. Finally, Citigroup upped their price objective on CRISPR Therapeutics from $53.00 to $83.00 and gave the company a “neutral” rating in a research report on Tuesday, August 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $112.33.

About CRISPR Therapeutics

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Read More

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.